annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 7C Phase I/II study of vandetanib for patients with recurrent malignant gliomas.
(Abstract #2083)
K. A. Mcnicol, T. N. Kreisl, F. M. Iwamoto, J. Sul, H. A. Fine
Brd. 7D Correlation of cognitive symptoms with cognitive performance among brain
cancer patients after radiation therapy. (Abstract #2084)
S. R. Rapp, L. D. Case, M. E. Loghin, C. A. Meyers, T. J. Saphner,
B. G. Sleckman, V. W. Stieber, J. N. Atkins, J. K. Giguere, E. G. Shaw
Brd. 7E A new gene expression-based diagnostic test to predict prognosis of
gliomas for the support of histopathologic diagnosis. (Abstract #2085)
K. Kato, M. Shirahata, S. Kawarazaki, R. Matoba, J. Takahashi
Brd. 7F Circulating endothelial cells, microparticles, and markers of inflammation
and coagulation in glioblastoma patients before and after protracted
temozolomide and radiotherapy. (Abstract #2086)
G. Reynes, V. Martinez-Sales, V. Vila, T. Fleitas, M. Martin, E. Reganon
Brd. 7G Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent
malignant glioma (MG). (Abstract #2087)
A. Benouaich-Amiel, E. Mazza, C. Massard, P. Gaviani, F. Fiorentini, A. Scaburri,
M. A. Pacciarini, E. Calvo
Brd. 8A CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a
phase II study in adults with recurrent glioblastoma. (Abstract #2089)
S. Gururangan, J. J. Vredenburgh, A. Desjardins, K. Peters, J. E. Herndon,
R. E. McLendon, D. Janney, H. S. Friedman, D. A. Reardon
Brd. 8B Assessment of diffusion parameters in scans prior to progression in GBM
patients following antiangiogenic therapy. (Abstract #2090)
L. Jalilian, E. Essock-Burns, S. Cha, S. M. Chang, N. A. Butowski, S. J. Nelson
Brd. 8C Study of quality of life in brain tumor patients treated with three-dimensional
conformal radiotherapy. (Abstract #2091)
V. S. Vankamamidi, V. R. Sunkavalli, K. J. Naidu, M. Malik, S. Pamidighantam
Brd. 8D Using a prospective comprehensive database to define features that impact
the outcome of patients with glioblastoma multiforme. (Abstract #2092)
K. M. Field, M. Rosenthal, S. Kosmider, P. Gibbs, K. Drummond
Brd. 8E Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and
systemic vaccination with tumor-lysate loaded dendritic cells in the stringent
syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma
immunity. (Abstract #2093)
P. R. Lowenstein, Y. Mineharu, G. King, M. Candolfi, W. Xiong, H. Assi, K. Yagiz,
K. Kroeger, S. Bannykh, M. Castro
Brd. 8F A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at
first progression. (Abstract #2094)
W. P. Mason, K. Belanger, G. A. Nicholas, I. Vallieres, D. Mathieu, A. Desjardins,
P. Kavan, A. M. Omuro, D. Reymond
Brd. 8G A clinical study investigating MPC-6827 with carboplatin in the treatment of
patients with relapsed glioblastoma multiforme. (Abstract #2095)
K. F. Grossmann, J. H. Ward, W. L. Akerley, M. J. Glantz, J. F. De Groot, R. Aiken,
J. J. Olson, Y. Matsuoka, M. K. Yu, R. L. Jensen
Brd. 9A Immune response correlation with progression-free survival in glioblastoma
following dendritic cell immunotherapy (ICT-107). (Abstract #2097)
S. Phuphanich, J. Rudnick, M. Mazer, H. Q. Wang, N. Serrano, J. Richardson,
C. Wheeler, M. Singh, K. Black, J. Yu
Brd. 9B New therapeutic approach for brain tumors: Intranasal administration of Ras
inhibitor perillyl alcohol. (Abstract #2098)
C. O. Fonseca
201
SUNDAY